Claims for Patent: 8,460,641

Summary for Patent: 8,460,641

Title:	Microemulsion process and composition
Abstract:	An oil-in-water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, comprising: a first part including at least one occlusive agent and one or more lipophilic surfactants dispersed throughout a second part including water and at least one hydrophilic surfactant, and a non-surfactant amphiphilic type compound, pharmaceutically active ingredient, and water. It has been found that if a non-surfactant amphiphilic type compound is added together with the second part as would conventionally be the case, a microemulsion or sub-micron emulsion is not formed, by adding the so called third part, phase assembly occurs at a lower temperature than would be expected and moreover, this phase appears to assist in maintaining the microemulsion or sub-micron emulsion characteristics of the formulation during storage at normal temperatures.
Inventor(s):	Larm; Maria Graziella (Rosanna, AU), Harding; Ronald (North Warrandyte, AU), Johnston; Michael (Yarraville, AU), Abram; Albert Zorko (Wantirna, AU), Vijayakumar; Prema (Fremont, CA), Sun; Phoebe (Mountain View, CA)
Assignee:	Stiefel Research Australia Pty Ltd (Rowville, AU)
Application Number:	11/216,668
Patent Claims:	1. An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, the composition comprising: at least one pharmaceutically active ingredient which is insoluble or only sparingly soluble in water; an oil in water microemulsion or sub-micron emulsion comprising an oil phase dispersed throughout a water phase, said oil phase comprising at least one occlusive agent selected from the group consisting of mineral oil, petrolatum, and mixtures thereof, and at least one lipophilic surfactant; and said water phase comprising at least one hydrophilic surfactant and water; a propellant; and a non-surfactant amphiphilic compound that is a water miscible organic solvent selected from the croup consisting of a glycol, a polyol, and mixtures thereof, wherein the non-surfactant amphiphilic compound is added to the composition after formation of the microemulsion or sub-micron emulsion and is miscible in said water phase, wherein the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant is approximately 9.0:1.0 to 2.0:3.0, and wherein the composition is dispensed as an aerosol foam or mousse and wherein said pharmaceutically active agent is in said water phase or wherein said pharmaceutically active agent is in both said oil phase and said water phase. 2. The composition of claim 1, wherein said surfactants have an aggregated HLB number between 8.0 and 15.0. 3. The composition of claim 1, wherein the pharmaceutically active agent is one or more water insoluble compounds selected from the group consisting of corticosteroids, desonide, clobetasol, betamethasone, vitamin D analogues and vitamin A analogues. 4. A method of medical or cosmetic treatment of a dermal condition, comprising: applying to the skin of a patient requiring such treatment an effective amount of oil in water microemulsion or sub-micron emulsion composition comprising at least one pharmaceutically active ingredient which is insoluble or only sparingly soluble in water; an oil in water microemulsion or sub-micron emulsion comprising an oil phase dispersed throughout a water phase, said oil phase comprising at least one occlusive agent selected from the group consisting of mineral oil, petrolatum, and mixtures thereof, and at least one lipophilic surfactant; and said water phase comprising at least one hydrophilic surfactant and water; a propellant; and a non-surfactant amphiphilic compound that is a water miscible organic solvent selected from the group consisting of a glycol, a polyol, and mixtures thereof, wherein the non-surfactant amphiphilic compound is added to the composition after formation of the microemulsion or sub-micron emulsion and is miscible in said water phase, wherein the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant is approximately 9.0:1.0 to 2.0:3.0, and wherein the composition is dispensed as an aerosol foam or mousse and wherein said pharmaceutically active agent is in said water phase or wherein said pharmaceutically active agent is in both said oil phase and said water phase. 5. The composition of claim 2, wherein said surfactants have an aggregated HLB number between 10 and 12. 6. The composition of claim 5, wherein said surfactants have an aggregated HLB number between 9.7 and 11.8. 7. The composition of claim 1, wherein said non-surfactant amphiphilic compound is propylene glycol. 8. The composition of claim 1, wherein said oil phase comprises mineral oil. 9. An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, the composition comprising: at least one pharmaceutically active ingredient which is insoluble or only sparingly soluble in water; an oil in water microemulsion or sub-micron emulsion comprising an oil phase dispersed throughout a water phase, said oil phase comprising at least one selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol, and at least one lipophilic surfactant, and said water phase comprising at least one hydrophilic surfactant and water; a propellant; and a non-surfactant amphiphilic compound that is added to the composition after formation of the microemulsion or sub-micron emulsion and is miscible in said water phase, wherein the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant is approximately 9.0:1.0 to 2.0:3.0, and wherein the composition is dispensed as an aerosol foam or mousse and wherein said pharmaceutically active agent is in said water phase or wherein said pharmaceutically active agent is in both said oil phase and said water phase. 10. The composition of claim 9, wherein said oil phase comprises at least one occlusive agent selected from the group consisting of mineral oil, petrolatum, and mixtures thereof, and at least one lipophilic surfactant. 11. The composition of claim 10, wherein said oil phase comprises mineral oil. 12. The composition of claim 9, wherein said amphipilic compound is a water miscible organic solvent selected from the group consisting of a glycol, a polyol, and mixtures thereof. 13. The composition of claim 9, wherein said surfactants have an aggregated HLB number between 8.0 and 15.0. 14. The composition of claim 13, wherein said surfactants have an aggregated HLB number between 10 and 12. 15. The composition of claim 14, wherein said surfactants have an aggregated HLB number between 9.7 and 11.8. 16. The composition of claim 9, wherein the pharmaceutically active agent is one or more water insoluble compounds selected from the group consisting of corticosteroids, desonide, clobetasol, betamethasone, vitamin D analogues and vitamin A analogues. 17. A method of medical or cosmetic treatment of a dermal condition, comprising: applying to the skin of a patient requiring such treatment an effective amount of oil in water microemulsion or sub-micron emulsion composition comprising at least one pharmaceutically active ingredient which is insoluble or only sparingly soluble in water; an oil in water microemulsion or sub-micron emulsion comprising an oil phase dispersed throughout a water phase, said oil phase comprising at least one of the group consisting of animal, mineral or vegetable oils, silanes, siloxanes, esters, fatty acids, fats, halogen compounds or alkoxylated alcohols, and at least one lipophilic surfactant; and said water phase comprising at least one hydrophilic surfactant and water; a propellant; and a non-surfactant amphiphilic compound that is added to the composition after formation of the microemulsion or sub-micron emulsion and is miscible in said water phase, wherein the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant is approximately 9.0:1.0 to 2.0:3.0, and wherein the composition is dispensed as an aerosol foam or mousse and wherein said pharmaceutically active agent is in said water phase or wherein said pharmaceutically active agent is in both said oil phase and said water phase. 18. The method of claim 17, wherein said oil phase comprises at least one occlusive agent selected from the group consisting of mineral oil, petrolatum, and mixtures thereof, and at least one lipophilic surfactant. 19. The method of claim 17, wherein said amphipilic compound is a water miscible organic solvent selected from the group consisting of a glycol, a polyol, and mixtures thereof. 20. The composition of claim 1, wherein the pharmaceutically active agent is a corticosteroid. 21. The composition of claim 9, wherein the pharmaceutically active agent is a corticosteroid.